Kura Oncology (KURA) Payables (2010 - 2026)

Kura Oncology (KURA) has 17 years of Payables data on file, last reported at $7.0 million in Q1 2026.

• Payables for Q1 2026 came in at $7.0 million, down 84.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (down 84.38% YoY), and the FY2025 annual result was $5.0 million, up 241.52% from the prior year.
• Payables improved to $7.0 million in Q1 2026 per KURA's latest filing, from $5.0 million in the prior quarter.
• Over five years, Payables peaked at $45.1 million in Q1 2025 and troughed at $1.3 million in Q1 2022.
• A 5-year average of $6.9 million and a median of $2.3 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2024: Payables slumped 93.96% in 2022, then jumped 839.02% in 2024.
• A 5-year view of Payables shows it stood at $1.5 million in 2022, then surged by 50.03% to $2.3 million in 2023, then plunged by 36.13% to $1.5 million in 2024, then soared by 241.52% to $5.0 million in 2025, then jumped by 40.38% to $7.0 million in 2026.
• Business Quant data shows KURA's Payables at $7.0 million in Q1 2026, $5.0 million in Q4 2025, and $4.7 million in Q3 2025.